VivoSeq
Neurology

Mild to Moderate Alzheimer's Disease

0

Pipeline Programs↗

9

Active Trials↗

34

Companies Involved↗

Mild to Moderate Alzheimer's Disease is an early-stage landscape with 0 programs across 34 companies. The most active players are Pfizer, Johnson & Johnson, GSK.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalC

Cognition Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

137

clinical trials

Completed95 · 69%
Terminated17 · 12%
Unknown status13 · 9%
Not yet recruiting4 · 3%
Recruiting3 · 2%
Active, not recruiting2 · 1%
Other3 · 2%

Clinical Trials

Trial Activity

137 trials

Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease
Recruiting·DDaewoong Bio Inc.·Phase 4·NCT05383183·630 enrolled
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
Recruiting·RRegeneration Biomedical, Inc.·Phase 1·NCT05667649·18 enrolled
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
Recruiting·II.R.C.C.S. Fondazione Santa Lucia·Phase 3·NCT06702124·348 enrolled
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
Active, not recruiting·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 2·NCT06881836·240 enrolled
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
Active, not recruiting·Roche logoRoche·Phase 1/2·NCT04639050·241 enrolled
Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease
Not yet recruiting·UUniversity of Saskatchewan·Phase 2·NCT07178678·90 enrolled
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
Not yet recruiting·TTabriz University of Medical Sciences·Phase 2·NCT06840054·30 enrolled
The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease
Not yet recruiting·XXuanwu Hospital, Beijing·Phase 1/2·NCT07457125·33 enrolled
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
Not yet recruiting·NNSC-Therapeutics·Phase 1/2·NCT06995573·90 enrolled
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
Completed·FFUJIFILM Toyama Chemical Co., Ltd.·Phase 2·NCT02079909·482 enrolled
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Completed·Pfizer logoPfizer·Phase 3·NCT00838110·742 enrolled
Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease
Completed·Pfizer logoPfizer·N/A·NCT00467766·300 enrolled
A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 1·NCT02127476·57 enrolled
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
Completed·GGeorgetown University·Phase 2·NCT02947893·37 enrolled
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
Completed·Pfizer logoPfizer·Phase 1·NCT00607308·20 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)